vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and GENCOR INDUSTRIES INC (GENC). Click either name above to swap in a different company.
GENCOR INDUSTRIES INC is the larger business by last-quarter revenue ($23.6M vs $16.1M, roughly 1.5× Journey Medical Corp). GENCOR INDUSTRIES INC runs the higher net margin — 14.6% vs -7.8%, a 22.4% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -25.0%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs -23.9%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Gencor Industries Inc is a leading manufacturer of heavy construction and infrastructure equipment, specializing in asphalt production plants, thermal combustion systems, and supporting road-building machinery. It primarily serves North American and global construction markets, supplying products to both public sector infrastructure projects and private commercial construction operators.
DERM vs GENC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $23.6M |
| Net Profit | $-1.2M | $3.4M |
| Gross Margin | — | 28.7% |
| Operating Margin | -2.8% | 13.2% |
| Net Margin | -7.8% | 14.6% |
| Revenue YoY | 27.3% | -25.0% |
| Net Profit YoY | -182.0% | -9.8% |
| EPS (diluted) | $-0.04 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $23.6M | ||
| Q3 25 | $17.0M | $18.8M | ||
| Q2 25 | $15.0M | $27.0M | ||
| Q1 25 | $13.1M | $38.2M | ||
| Q4 24 | $12.6M | $31.4M | ||
| Q3 24 | $14.6M | $20.9M | ||
| Q2 24 | $14.9M | $25.6M | ||
| Q1 24 | $13.0M | $40.7M |
| Q4 25 | $-1.2M | $3.4M | ||
| Q3 25 | $-2.3M | $1.9M | ||
| Q2 25 | $-3.8M | $3.8M | ||
| Q1 25 | $-4.1M | $6.1M | ||
| Q4 24 | $1.5M | $3.8M | ||
| Q3 24 | $-2.4M | $1.5M | ||
| Q2 24 | $-3.4M | $2.6M | ||
| Q1 24 | $-10.4M | $6.2M |
| Q4 25 | — | 28.7% | ||
| Q3 25 | — | 24.2% | ||
| Q2 25 | — | 26.5% | ||
| Q1 25 | — | 29.7% | ||
| Q4 24 | 82.3% | 27.6% | ||
| Q3 24 | 63.9% | 25.6% | ||
| Q2 24 | 56.0% | 23.9% | ||
| Q1 24 | 47.7% | 30.3% |
| Q4 25 | -2.8% | 13.2% | ||
| Q3 25 | -9.0% | -1.2% | ||
| Q2 25 | -19.2% | 11.6% | ||
| Q1 25 | -25.3% | 17.0% | ||
| Q4 24 | 17.7% | 14.7% | ||
| Q3 24 | -19.8% | 5.9% | ||
| Q2 24 | -19.7% | 7.8% | ||
| Q1 24 | -77.4% | 17.4% |
| Q4 25 | -7.8% | 14.6% | ||
| Q3 25 | -13.6% | 10.2% | ||
| Q2 25 | -25.3% | 14.2% | ||
| Q1 25 | -31.0% | 16.0% | ||
| Q4 24 | 12.1% | 12.1% | ||
| Q3 24 | -16.3% | 6.9% | ||
| Q2 24 | -22.6% | 10.0% | ||
| Q1 24 | -80.1% | 15.3% |
| Q4 25 | $-0.04 | $0.23 | ||
| Q3 25 | $-0.09 | $0.13 | ||
| Q2 25 | $-0.16 | $0.26 | ||
| Q1 25 | $-0.18 | $0.42 | ||
| Q4 24 | $0.10 | $0.26 | ||
| Q3 24 | $-0.12 | $0.10 | ||
| Q2 24 | $-0.17 | $0.17 | ||
| Q1 24 | $-0.53 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $147.7M |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $215.2M |
| Total Assets | $94.6M | $228.9M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $147.7M | ||
| Q3 25 | $24.9M | $136.3M | ||
| Q2 25 | $20.3M | $136.0M | ||
| Q1 25 | $21.1M | $143.7M | ||
| Q4 24 | $20.3M | $130.1M | ||
| Q3 24 | $22.5M | $115.4M | ||
| Q2 24 | $23.9M | $116.6M | ||
| Q1 24 | $24.1M | $117.1M |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | $0 | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | $0 | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $215.2M | ||
| Q3 25 | $25.9M | $211.8M | ||
| Q2 25 | $19.2M | $209.9M | ||
| Q1 25 | $21.5M | $206.1M | ||
| Q4 24 | $20.1M | $200.0M | ||
| Q3 24 | $10.9M | $196.1M | ||
| Q2 24 | $11.3M | $194.7M | ||
| Q1 24 | $13.0M | $192.1M |
| Q4 25 | $94.6M | $228.9M | ||
| Q3 25 | $85.2M | $222.6M | ||
| Q2 25 | $81.2M | $220.2M | ||
| Q1 25 | $85.0M | $223.9M | ||
| Q4 24 | $80.2M | $218.2M | ||
| Q3 24 | $64.0M | $208.1M | ||
| Q2 24 | $65.2M | $201.8M | ||
| Q1 24 | $66.6M | $206.0M |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | 0.00× | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | 0.00× | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $11.1M |
| Free Cash FlowOCF − Capex | — | $10.1M |
| FCF MarginFCF / Revenue | — | 43.0% |
| Capex IntensityCapex / Revenue | — | 4.1% |
| Cash ConversionOCF / Net Profit | — | 3.23× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-3.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $11.1M | ||
| Q3 25 | $-2.4M | $-275.0K | ||
| Q2 25 | $-942.0K | $-23.9M | ||
| Q1 25 | $-2.8M | $12.4M | ||
| Q4 24 | $2.2M | $14.8M | ||
| Q3 24 | $-1.2M | $-3.2M | ||
| Q2 24 | $-5.2M | $-1.0M | ||
| Q1 24 | $-5.0M | $11.7M |
| Q4 25 | — | $10.1M | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | — | $-24.4M | ||
| Q1 25 | — | $12.3M | ||
| Q4 24 | — | $14.5M | ||
| Q3 24 | — | $-3.3M | ||
| Q2 24 | — | $-1.4M | ||
| Q1 24 | — | $11.7M |
| Q4 25 | — | 43.0% | ||
| Q3 25 | — | -6.8% | ||
| Q2 25 | — | -90.4% | ||
| Q1 25 | — | 32.2% | ||
| Q4 24 | — | 46.1% | ||
| Q3 24 | — | -15.8% | ||
| Q2 24 | — | -5.6% | ||
| Q1 24 | — | 28.7% |
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | — | 0.4% | ||
| Q2 24 | — | 1.5% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | 3.23× | ||
| Q3 25 | — | -0.14× | ||
| Q2 25 | — | -6.24× | ||
| Q1 25 | — | 2.04× | ||
| Q4 24 | 1.46× | 3.88× | ||
| Q3 24 | — | -2.22× | ||
| Q2 24 | — | -0.41× | ||
| Q1 24 | — | 1.87× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
GENC
Segment breakdown not available.
